Source:http://linkedlifedata.com/resource/pubmed/id/10398079
Switch to
Predicate | Object |
---|---|
rdf:type | |
lifeskim:mentions | |
pubmed:issue |
3
|
pubmed:dateCreated |
1999-8-23
|
pubmed:abstractText |
Cyclin D1 (CCND1) amplification is found in 10-15 per cent of invasive breast carcinomas, but it is not well established whether this gene alteration also occurs in the precursor of invasive breast carcinoma, ductal carcinoma in situ (DCIS). By Southern blot analysis, cyclin D1 gene amplification was detected in 10 per cent (3/32) of DCIS cases. In addition, 15 cases of DCIS were analysed using bright field in situ hybridization (BRISH), of which 11 had already been analysed by Southern blotting. One additional case with gene amplification was found by BRISH. The use of BRISH for the detection of gene amplification is shown to be a novel and reliable in situ method on paraffin-embedded tissue sections. By immunohistochemistry, 147 cases of DCIS were analysed for the expression of cyclin D1. Cyclin D1 overexpression was found in 9 per cent of well-differentiated, 29 per cent of intermediately differentiated, and 19 per cent of poorly differentiated DCIS. No statistically significant association was found between cyclin D1 overexpression and the differentiation grade of DCIS, although 90 per cent of the cases that show overexpression are classified as intermediately and poorly differentiated. An association was found between cyclin D1 overexpression and oestrogen receptor positivity. Cyclin D1 overexpression was found in all four cases with cyclin D1 gene amplification, but was also found in 30 per cent (8/27) of cases without detectable gene amplification. It is concluded that cyclin D1 gene amplification is an early event in the development of breast carcinoma and occurs in poorly differentiated DCIS. Cyclin D1 protein overexpression is also present in tumours without cyclin D1 gene amplification and is seen predominantly in DCIS of intermediately and poorly differentiated histological type and oestrogen receptor positivity.
|
pubmed:language |
eng
|
pubmed:journal | |
pubmed:citationSubset |
IM
|
pubmed:chemical | |
pubmed:status |
MEDLINE
|
pubmed:month |
Feb
|
pubmed:issn |
0022-3417
|
pubmed:author | |
pubmed:issnType |
Print
|
pubmed:volume |
187
|
pubmed:owner |
NLM
|
pubmed:authorsComplete |
Y
|
pubmed:pagination |
279-84
|
pubmed:dateRevised |
2006-11-15
|
pubmed:meshHeading |
pubmed-meshheading:10398079-Blotting, Southern,
pubmed-meshheading:10398079-Breast Neoplasms,
pubmed-meshheading:10398079-Carcinoma, Ductal, Breast,
pubmed-meshheading:10398079-Carcinoma in Situ,
pubmed-meshheading:10398079-Cyclin D1,
pubmed-meshheading:10398079-Female,
pubmed-meshheading:10398079-Gene Expression,
pubmed-meshheading:10398079-Genes, bcl-1,
pubmed-meshheading:10398079-Humans,
pubmed-meshheading:10398079-Immunoenzyme Techniques,
pubmed-meshheading:10398079-In Situ Hybridization,
pubmed-meshheading:10398079-Neoplasm Proteins,
pubmed-meshheading:10398079-Receptors, Estrogen
|
pubmed:year |
1999
|
pubmed:articleTitle |
Cyclin D1 gene amplification and overexpression are present in ductal carcinoma in situ of the breast.
|
pubmed:affiliation |
Department of Pathology, Leiden University Medical Centre, The Netherlands.
|
pubmed:publicationType |
Journal Article,
Research Support, Non-U.S. Gov't
|